SCHEMBL911298

SCHEMBL911298

Cc1ccc(CC[C]=O)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.50
CYP2A6 P11509 1/20 0.50
TAAR1 Q96RJ0 1/20 0.50
FFAR1 O14842 1/20 0.44
IDO1 P14902 1/20 0.42
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
KMT2A Q03164 1/20 0.41
KCNH2 Q12809 3/20 0.41
HRH3 Q9Y5N1 1/20 0.41
TDP1 Q9NUW8 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
IGF1R P08069 1/20 0.39
ALOX15 P16050 1/20 0.39
DAO P14920 2/20 0.39
ACHE P22303 1/20 0.38
AGXT P21549 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9206133 0.87 GFER (0.36) CYP1A2CYP2A6TAAR1FFAR1MEN1
SCHEMBL3249510 0.86 CYP1A2 (0.46) CYP1A2CYP2A6TAAR1FFAR1IDO1
SCHEMBL910881 0.81 CA2 (0.47) ALDH1A1KMT2AL3MBTL1NPC1RAB9A
SCHEMBL910426 0.81 TAAR1 (0.50) CYP2A6TAAR1ALDH1A1TDP1L3MBTL1
SCHEMBL9678338 0.78 KCNH2 (0.54) CYP1A2CYP2A6TAAR1FFAR1MEN1
SCHEMBL1610569 0.76 CYP1A2 (0.50) CYP1A2CYP2A6TAAR1FFAR1IDO1
SCHEMBL5540673 0.76 PGK1 (0.35) TAAR1FFAR1ALDH1A1RAB9AMAPT
SCHEMBL8439000 0.76 HRH3 (0.46) TAAR1HRH3MAPT
SCHEMBL980506 0.76 TAAR1 (0.50) TAAR1FFAR1IDO1DAOAGXT
SCHEMBL440374 0.76 TAAR1 (0.50) CYP1A2TAAR1IDO1MEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106414480-B Polymyxin derivatives as antimicrobial compounds 莫纳什大学 2020-08-04 CN claimed
US-20130045942-A1 N6-SUBSTITUTED ADENOSINE DERIVATIVES AND N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2013-02-21 US claimed
EP-2511283-A1 N6-SUBSTITUTED ADENOSINE DERIVATIVES, N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2012-10-17 EP claimed
CN-101500996-B (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives ACTELION PHARMACEUTICALS LTD 2012-07-04 CN claimed
WO-2009108364-A2 ANTAGONISTIC ANALOGUES OF GHRH IPSEN PHARMA S.A.S. (FR) 2009-09-03 WO claimed
US-10550153-B2 Peptide or pharmaceutically acceptable salt thereof, or prodrug thereof TOKYO UNIVERSITY OF PHARMACY & LIFE SCIENCES (JP) 2020-02-04 US disclosed
US-10174033-B2 N6-substituted adenosine derivatives and N6-substituted adenine derivatives and uses thereof INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2019-01-08 US disclosed
US-8937090-B2 Parakeratosis inhibitor, pore-shrinking agent and external composition for skin SHISEIDO COMPANY, LTD. (JP) 2015-01-20 US disclosed
US-20140178606-A1 CELLULOSE ACYLATE FILM, POLARIZER, AND LIQUID CRYSTAL DISPLAY DEVICE FUJIFILM CORPORATION (JP) 2014-06-26 US disclosed
US-20130128359-A1 OPTICAL FILM, POLARIZING PLATE, AND LIQUID CRYSTAL DISPLAY APPARATUS FUJIFILM CORPORATION (JP) 2013-05-23 US disclosed
EP-2593426-A1 1-HYDROXYIMINO-3-PHENYL-PROPANES F.HOFFMANN-LA ROCHE AG (CH) 2013-05-22 EP disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1095947-A1 NOVEL ANTIBACTERIAL COMPOUNDS Sankyo Company Limited (JP) 2001-05-02 EP disclosed
US-4576753-A MICROBIOCIDES, ANTIBIOTICS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1986-03-18 US disclosed
US-4472309-A ANTIMICROBIAL FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1984-09-18 US disclosed
US-4438277-A Hydronaphthalene derivatives SANKYO COMPANY, LIMITED (JP) 1984-03-20 US disclosed
US-4361515-A Antihyperlipemic dihydro-ML-236B derivatives, their preparation and use SANKYO COMPANY, LIMITED (JP) 1982-11-30 US disclosed
US-4304718-A ANTIBIOTICS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1981-12-08 US disclosed
US-4264498-A REACTED WITH AN ACID, ITS ACID HALIDE, OR ANHYDRIDE IN THE PRESENCE OF BORON TRIHALIDE AND AN ORGANIC BASE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1981-04-28 US disclosed
US-4181800-A ANTIBIOTICS FROM SUBSTITUTED PERHYDRO-S-TRIAZINES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1980-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10550153-B2 Peptide or pharmaceutically acceptable salt thereof, or prodrug thereof NMUR2, NMUR1, NTSR2 CYP1A2 3184/4885CYP2A6 3375/4885TAAR1 691/4885
US-10174033-B2 N6-substituted adenosine derivatives and N6-substituted adenine derivatives and uses thereof ADORA2A, ADORA3, ADORA1 CYP1A2 367/4885CYP2A6 243/4885TAAR1 1309/4885
US-20130045942-A1 N6-SUBSTITUTED ADENOSINE DERIVATIVES AND N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF ADORA2A, ADORA3, ADORA1 CYP1A2 367/4885CYP2A6 243/4885TAAR1 1309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.